Beximco Pharmaceuticals Ltd. (R2WA)
FSX
0.4000
0.00 (0.00%)
Closed
Oct 5, 2026
Day's Range
0.40000.4000
52 wk Range
0.40000.4000
Financial Statements - R2WA - Beximco Pharmaceuticals Ltd.
Revenue
49.12B▲ 10.7%
Net Income
6.99B▲ 19.3%Net Margin 14.2%
EBITDA
11.95B▲ 12.4%
Free Cash Flow
4.19B▼ 31.6%
Income Statement
| Period Ending | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|---|
| Sales | 49.12B | 44.39B | 39.26B | 34.66B | 29.49B | 25.61B |
| Cost of Goods | 26.82B | 24.75B | 21.96B | 18.84B | 15.57B | 13.71B |
| Gross Profit | 22.29B | 19.63B | 17.30B | 15.82B | 13.92B | 11.89B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 9.61B | 8.58B | 7.17B | 6.84B | 6.65B | 5.51B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 9B | 7.52B | 6.06B | 6.68B | 6.37B | 4.65B |
| Income Tax | 2B | 1.65B | 1.54B | 1.68B | 1.21B | 1.10B |
| Net Income | 6.99B | 5.86B | 4.52B | 4.99B | 5.16B | 3.54B |
| EPS Basic | 15.56 | 13.07 | 10.34 | 11.48 | 11.49 | 7.881818 |
| EPS Diluted | 15.56 | 13.07 | 10.34 | 11.48 | 11.49 | 7.881818 |
| Basic Shares Outstanding | 446.11M | 446.11M | 446.23M | 56.39B | 56.39B | 56.35B |
| Diluted Shares Outstanding | 446.11M | 446.11M | 446.23M | 56.39B | 56.39B | 56.35B |
| Ebit | 9.96B | 8.64B | 7.31B | 7.61B | 7.18B | 5.63B |
| Ebitda | 11.95B | 10.64B | 9.36B | 9.32B | 7.40B | 5.86B |
| Net Income Continuous Operations | 6.99B | 5.86B | 4.52B | 4.99B | - | - |
| Minority Interests | -58.24M | -37.24M | 89.59M | 124.50M | -38.05M | -29.79M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
